Provider perceptions and insights on polygenic risk scores for colorectal cancer: A qualitative study
Journal of Genetic Counseling · 2025
DOI: 10.1002/jgc4.70135 ↗Kurz gefasst
Qualitative Studie in der Zeitschrift Journal of Genetic Counseling, 2025. Verfasst von Shenazar Esmundo und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars Sinai Medical Center, Los Angeles, California, USA. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Genetic Predisposition to Disease, Health Personnel, Multifactorial Inheritance. Die Arbeit nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDDK NIH HHS, Cedars-Sinai Medical Center.
Abstract (Originalsprache)
Polygenic risk scores (PRS), a measure that sums multiple common genetic susceptibility variants into a single burden measure, can help identify individuals at higher risk for colorectal cancer (CRC). Consequently, there is growing interest in its potential use to guide screening practices, despite the current lack of evidence‐based guidelines on the clinical utility of PRS models. Therefore, there is a need to understand the potential challenges and factors associated with PRS use in primary care settings. This qualitative study explores the perceptions of healthcare providers with PRS information to guide CRC screening decisions in the primary care setting. Using an exploratory approach, we conducted semi‐structured interviews with 10 healthcare providers. The socioecological model guided the development of the interview questions. Transcripts were coded based on emergent themes. A total of seven themes were identified in this study, and each was organized using the socioecological model at the individual, interpersonal, community, and organizational levels. One key finding was the limited knowledge of PRS and the distinction between PRS and genetic testing for high‐penetrant germline mutations. Providers shared the need for training, education, and comprehensive clinical guidelines for the use of PRS. This study provides insights to better optimize genetic education, testing, access, and care for improved CRC screening in at‐risk individuals.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars Sinai Medical Center, Los Angeles, California, USA.
- Cedars-Sinai Cancer Research Center for Health Equity, Cedars-Sinai Medical Center, Los Angeles, California, USA.
- University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California, USA.
- Los Angeles General Medical Center, Los Angeles, California, USA.
- Division of Gastroenterology, City of Hope, Duarte, California, USA.
- Division of Population Sciences, Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Förderung
- NIDDK NIH HHS
- Cedars-Sinai Medical Center
Zitieren
APA
Esmundo, S., Caceres, N., Ricker, C., Idos, G. E., Loroña, N. C., Castellon-Lopez, Y., Schmit, S. L., Meade, C. D., Gwede, C. K., Nguyen, N. T., & Figueiredo, J. C. (2025). Provider perceptions and insights on polygenic risk scores for colorectal cancer: A qualitative study. Journal of Genetic Counseling. https://doi.org/10.1002/jgc4.70135
Vancouver
Esmundo S, Caceres N, Ricker C, Idos GE, Loroña NC, Castellon-Lopez Y, et al. Provider perceptions and insights on polygenic risk scores for colorectal cancer: A qualitative study. Journal of Genetic Counseling. 2025. doi:10.1002/jgc4.70135
BibTeX
@article{Esmundo2025,
author = {Esmundo, Shenazar and Caceres, Nenette and Ricker, Charité and Idos, Gregory E and Loroña, Nicole C and Castellon-Lopez, Yelba and Schmit, Stephanie L and Meade, Cathy D and Gwede, Clement K and Nguyen, Nathalie T and Figueiredo, Jane C},
title = {Provider perceptions and insights on polygenic risk scores for colorectal cancer: A qualitative study},
journal = {Journal of Genetic Counseling},
year = {2025},
doi = {10.1002/jgc4.70135}
}
EUVIMED